Peter Chin - Denali Therapeutics Senior Affairs
| DNLI Stock | USD 24.22 0.20 0.82% |
Executive
Peter Chin is Senior Affairs of Denali Therapeutics
| Address | 161 Oyster Point Boulevard, South San Francisco, CA, United States, 94080 |
| Phone | 650 866 8548 |
| Web | https://www.denalitherapeutics.com |
Denali Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2381) % which means that it has lost $0.2381 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3509) %, meaning that it created substantial loss on money invested by shareholders. Denali Therapeutics' management efficiency ratios could be used to measure how well Denali Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.13. The current Return On Capital Employed is estimated to decrease to -0.19. As of now, Denali Therapeutics' Non Current Assets Total are increasing as compared to previous years. The Denali Therapeutics' current Non Currrent Assets Other is estimated to increase to about 19.1 M, while Total Assets are projected to decrease to under 932.8 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Andrew Funderburk | Monte Rosa Therapeutics | N/A | |
| Casey Logan | Travere Therapeutics | N/A | |
| Scott Holmes | Ascendis Pharma AS | N/A | |
| Moriarty ESQ | Avidity Biosciences | 56 | |
| Pr MD | Apellis Pharmaceuticals | N/A | |
| Christina MBA | Blueprint Medicines Corp | 48 | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Doug Wallace | Legend Biotech Corp | N/A | |
| Tina Carter | Legend Biotech Corp | N/A | |
| Yan Qi | BeiGene | N/A | |
| Patrick Lamy | Akero Therapeutics | 51 | |
| Kathryn Haviland | Blueprint Medicines Corp | 48 | |
| Christopher CFA | Travere Therapeutics | 39 | |
| Bob Lally | Ikena Oncology | N/A | |
| Shamim MS | Stoke Therapeutics | 64 | |
| Edmund Dunn | Monte Rosa Therapeutics | 58 | |
| Jula MD | Travere Therapeutics | 49 | |
| Charlotte Smith | Travere Therapeutics | N/A | |
| David JD | Akero Therapeutics | N/A | |
| John III | Avidity Biosciences | 66 | |
| Scott Gangloff | Akero Therapeutics | 50 | |
Management Performance
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.24 |
Denali Therapeutics Leadership Team
Elected by the shareholders, the Denali Therapeutics' board of directors comprises two types of representatives: Denali Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Denali. The board's role is to monitor Denali Therapeutics' management team and ensure that shareholders' interests are well served. Denali Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Denali Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peter Chin, Senior Affairs | ||
| Carole MD, Chief Development | ||
| Mark Rowen, Vice Development | ||
| Chris Walsh, General Counsel | ||
| Ryan Watts, President CEO, Co-Founder, Director | ||
| Steve Krognes, Treasurer Director | ||
| Dana Andersen, CTO and Manufacturing Officer | ||
| Tyler Nielsen, Senior Finance | ||
| Cindy Dunkle, Chief Officer | ||
| Joe Lewcock, Chief Officer | ||
| Laura Hansen, Vice Relations | ||
| Chris JD, General Counsel | ||
| Alexander MD, CFO, CoFounder | ||
| Marc TessierLavigne, Chairman CoFounder | ||
| Tony Estrada, Senior Sciences | ||
| Katie Peng, Chief Officer |
Denali Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Denali Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | 2.73 B | ||||
| Shares Outstanding | 143.92 M | ||||
| Shares Owned By Insiders | 9.63 % | ||||
| Shares Owned By Institutions | 90.58 % | ||||
| Number Of Shares Shorted | 7.43 M | ||||
| Price To Earning | 60.91 X | ||||
| Price To Book | 2.67 X | ||||
| Price To Sales | 3,339 X |
Currently Active Assets on Macroaxis
When determining whether Denali Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Denali Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Denali Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Denali Therapeutics Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.76) | Quarterly Revenue Growth (1.00) | Return On Assets (0.24) | Return On Equity (0.35) |
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.